<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221906</url>
  </required_header>
  <id_info>
    <org_study_id>BOS-475-102</org_study_id>
    <secondary_id>2019-002447-17</secondary_id>
    <nct_id>NCT04221906</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test</brief_title>
  <official_title>A Phase Ib, Multi-Center, Randomized, Vehicle- and Comparator-Controlled Trial, Double-Blind for the Investigational Medicinal Products, Observer-Blind for the Comparators to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate the safety of topical BOS-475 compared to topically
      applied comparator formulations and vehicle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a three-center, randomized, placebo- and comparator-controlled, double-blind for the
      Investigational Medicinal Products (IMPs), observer-blind for the controls, intraindividual
      comparison of all 6 treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 6, 2020</start_date>
  <completion_date type="Actual">March 6, 2020</completion_date>
  <primary_completion_date type="Actual">March 6, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>up to Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of treatment-emergent application site reactions</measure>
    <time_frame>up to Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in systolic and diastolic blood pressure</measure>
    <time_frame>Baseline; up to Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in pulse</measure>
    <time_frame>Baseline; up to Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in respiration</measure>
    <time_frame>Baseline; up to Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in body temperature</measure>
    <time_frame>Baseline; up to Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant physical examination findings</measure>
    <time_frame>up to Day 19</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in psoriatic infiltrate thickness on Day 19 (assessed by measurement of the thickness of the Echo Poor Band [EPB] of the inflammatory infiltrate using 22-megahertz (MHz) sonography)</measure>
    <time_frame>Baseline; Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in psoriatic infiltrate thickness on Days 8 and 15 (assessed by measurement of the thickness of the EPB of the inflammatory infiltrate using 22-MHz sonography)</measure>
    <time_frame>Baseline; Days 8 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) of change from Baseline in thickness of the EPB of the inflammatory infiltrate</measure>
    <time_frame>Baseline; Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the test fields compared to the surrounding plaque skin, as an evaluation of the antipsoriatic efficacy by clinical assessment, using a 5-point score</measure>
    <time_frame>Baseline; Days 1, 8, 15, and 19 (End of Trial)</time_frame>
    <description>-1 = worsened; 0 = unchanged (no effect); 1 = slight improvement; 2 = clear improvement but not completely healed; 3 = completely healed.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Chronic Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>BOS-475 0.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily application of BOS-475 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOS-475 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily application of BOS-475 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOS-475 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily application of BOS-475 2%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active ingredient-free vehicle cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily application of vehicle cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daivonex cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily application of Daivonex cream (calcipotriol 0.005%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Betnesol-V cream (betamethasone 0.1%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily application of Betnesol-V cream (betamethasone 0.1%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOS-475</intervention_name>
    <description>topical cream</description>
    <arm_group_label>BOS-475 0.5%</arm_group_label>
    <arm_group_label>BOS-475 1%</arm_group_label>
    <arm_group_label>BOS-475 2%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active ingredient-free vehicle cream</intervention_name>
    <description>topical cream</description>
    <arm_group_label>Active ingredient-free vehicle cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daivonex cream (calcipotriol 0.005%)</intervention_name>
    <description>topical cream</description>
    <arm_group_label>Daivonex cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betnesol-V cream (betamethasone 0.1%)</intervention_name>
    <description>topical cream</description>
    <arm_group_label>Betnesol-V cream (betamethasone 0.1%)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men, or women of non-childbearing potential aged 18-69 years (inclusive)

          -  Participants with chronic stable plaque psoriasis

          -  The target lesion(s) should be on the trunk or extremities (excluding palms/soles);
             psoriatic lesions on the knees or elbows are not to be used as target lesions.

          -  Willing and able to follow all trial procedures and complete the whole trial

          -  Capable of giving signed informed consent which includes compliance with the
             requirements and restrictions listed in the Informed Consent Form (ICF) and in this
             protocol

          -  Willing to refrain from using any topical treatments on the target areas, other than
             those mandated by the protocol or for protocol procedures

        Exclusion Criteria:

          -  Other skin disease or infection that is considered by the investigator to be relevant
             to the outcome of the trial

          -  Participants with acute psoriasis guttata, psoriasis punctata, psoriasis
             erythrodermatica or pustular psoriasis

          -  Any topical antipsoriatics on plaques potentially to be treated in this trial
             (including corticosteroids, vitamin D analogues, immunomodulators, retinoids,
             dithranol and tar) in the 4 weeks before first treatment and/or during the trial
             (pretreatment with salicylic acid is permitted on selected plaques; treatment on the
             face, ears and scalp is also permitted as lesions are not involved in the trial)

          -  Systemic treatment with antipsoriatics, e.g., corticosteroids, cytostatics, retinoids,
             dimethylfumarate or apremilast in the three months before first treatment and during
             the trial

          -  Systemic treatment with biological treatments: ustekinumab or secukinumab within six
             months or adalimumab, infliximab, and etanercept within three months before first
             treatment and during the trial. Any other previously used biologics for treatment of
             psoriasis should have been washed out for five half lives before first treatment.

          -  Ultraviolet A (UVA) or B-therapy within four weeks and psoralen and ultraviolet A
             (PUVA)-therapy within eight weeks before first treatment and during the trial
             treatment with concomitant medication that may affect and provoke or aggravate
             psoriasis, e.g., antimalarial drugs, lithium, beta-blockers, or
             angiotensin-converting-enzyme (ACE) inhibitors unless on a stable dose for 3 months
             before trial medication initiation

          -  History of malignancy within 5 years prior to dosing, except adequately treated
             non-invasive skin cancer (basal or squamous cell carcinoma

          -  Positive urine drug or breath alcohol test results during screening or at Day 1, or
             history of drug abuse within a year prior to the screening visit

          -  Excess alcohol consumption within 6 months prior to the trial defined as an average
             weekly intake of &gt; 14 units for males and females. One unit is equivalent to 8 grams
             of alcohol: a half-pint (~240 milliliters [mL]) of beer, 1 glass (125 mL) of wine, or
             1 (25 mL) measure of spirits

          -  Blood pressure (BP) &gt;160 millimeters of mercury (mmHg) systolic or &gt;95 mmHg diastolic
             at screening

          -  Participation in another clinical trial within the last six months for biological
             agents, or four weeks for small molecules prior to first treatment in this clinical
             trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaobing Qian, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Boston Pharmaceuticals, Vice President, Clinical Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. med. Johannes Niesmann und Dr. med. Nick Othlinghaus Hauszentrum im Jahrhunderthaus - Zentrum f√ºr klinische Studien</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>bioskin GmbH</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Schwerin GmbH</name>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BOS-475</keyword>
  <keyword>antipsoriatic efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>psoriasis plaque test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

